Quick Answer
enGene Therapeutics Inc. reported Net Income of -$117.30 million for fiscal year 2025.
enGene Therapeutics Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$117.30M | -112.7% |
| 2024 | -$55.14M | +44.8% |
| 2023 | -$99.92M | -308.5% |
| 2022 | -$24.46M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | -$29.75M | -20.9% | -2.6% |
| July 31, 2025 | -$28.99M | -104.9% | -12.3% |
| April 30, 2025 | -$25.82M | -72.3% | -4.9% |
| January 31, 2025 | -$24.62M | -129.8% | -74.0% |
| July 31, 2024 | -$14.15M | -199.7% | +5.6% |
| April 30, 2024 | -$14.98M | -183.7% | -39.9% |
| January 31, 2024 | -$10.71M | -44.4% | -126.9% |
| July 31, 2023 | -$4.72M | — | +10.6% |
- enGene Therapeutics Inc. showed a decrease of -112.7% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, enGene Therapeutics Inc.’s net income has declined by 379.5% (from -$24.46 million to -$117.30 million).
- The most recent figure is from enGene Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: